Cite
RASSF6-mediated inhibition of Mcl-1 through JNK activation improves the anti-tumor effects of sorafenib in renal cell carcinoma.
MLA
Liang, Ying-Ying, et al. “RASSF6-Mediated Inhibition of Mcl-1 through JNK Activation Improves the Anti-Tumor Effects of Sorafenib in Renal Cell Carcinoma.” Cancer Letters, vol. 432, Sept. 2018, pp. 75–83. EBSCOhost, https://doi.org/10.1016/j.canlet.2018.05.048.
APA
Liang, Y.-Y., Deng, X.-B., Zeng, L.-S., Lin, X.-T., Shao, X.-F., Wang, B., Mo, Z.-W., & Yuan, Y.-W. (2018). RASSF6-mediated inhibition of Mcl-1 through JNK activation improves the anti-tumor effects of sorafenib in renal cell carcinoma. Cancer Letters, 432, 75–83. https://doi.org/10.1016/j.canlet.2018.05.048
Chicago
Liang, Ying-Ying, Xu-Bin Deng, Li-Si Zeng, Xian-Tao Lin, Xun-Fan Shao, Bin Wang, Zhi-Wen Mo, and Ya-Wei Yuan. 2018. “RASSF6-Mediated Inhibition of Mcl-1 through JNK Activation Improves the Anti-Tumor Effects of Sorafenib in Renal Cell Carcinoma.” Cancer Letters 432 (September): 75–83. doi:10.1016/j.canlet.2018.05.048.